Do Certain Medications Increase the Risk of MS Development?
No drug treatments were conclusively associated with an increased risk of MS.
YIR 2017 Neurology
Soliris Approved to Treat Generalized Myasthenia Gravis
The FDA based its approval of the extended indication for Soliris on comprehensive clinical data from the Phase 3, randomized, double-blind, placebo-controlled, multicenter REGAIN study (ECU-MG-301).
FDA Approves Treatment for Two Neuropathic Pain Conditions
The efficacy of Lyrica CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.
Adverse Effects Compared for Multiple Parkinson’s Disease Drugs
The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea.
Gocovri Approved to Treat Dyskinesia in Patients with Parkinson’s Disease
The safety and efficacy of Gocovri was seen in two Phase 3 controlled trials in Parkinson’s disease patients with dyskinesia.
Law Enforcement Data Indicate a Rise in Gabapentin Misuse
Using data from the Drug Diversion Program of the Researched Abuse, Diversion, and Addiction-Related Surveillance System, the authors were able to calculate the rates of gabapentin diversion (per 100,000 population) for each quarter from 2002-2015
FDA Approves First New ALS Drug in Over 20 Years
The FDA’s decision was supported by data from a clinical development program that lasted 13 years with multiple Phase 3 studies.
Austedo Approved for Huntington’s Disease
Austedo, a vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first deuterated product approved by the FDA.
Ocrevus Approved for Relapsing, Primary Progressive MS
This is the first drug approved for primary progressive MS.
FDA Approves New Parkinson’s Disease Treatment
Data showed Xadago statistically and significantly increased “on” time without troublesome dyskinesia.
